Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biogen Idec (NQ:BIIB)

186.38 -2.90 (-1.53%)
Streaming Delayed Price Updated: 1:09 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
49 50 Next >
News headline image
Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings ↗
Biogen (NASDAQ:BIIB) reported strong Q1 earnings, beating expectations. However, they cut their FY2026 EPS guidance. Analysts have mixed opinions on buying BIIB stock. 
Via Benzinga
News headline image
Why Biogen Stock Was a Winner on Wednesday ↗
The biotech's growth portfolio continues to add to its overall top line. 
Via The Motley Fool
News headline image
Biogen (BIIB) Q1 2026 Earnings Transcript ↗
Biogen (BIIB) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Biogen (NASDAQ:BIIB) Surprises With Q1 CY2026 Sales
Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 1.9% year on year to $2.48 billion. Its... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before the bell. Here’s what you need to know. Biogen beat analysts’ revenue ex... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Profitable Stocks We Steer Clear Of
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
Biogen (BIIB) Q4 2024 Earnings Call Transcript ↗
Biogen (BIIB) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Biogen (BIIB) Q3 2024 Earnings Transcript ↗
Biogen (BIIB) Q3 2024 Earnings Transcript 
Via The Motley Fool
News headline image
Biogen (BIIB) Q2 2025 Earnings Transcript ↗
Biogen (BIIB) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Biogen (BIIB) Q3 2025 Earnings Transcript ↗
Biogen (BIIB) Q3 2025 Earnings Transcript 
Via The Motley Fool
Topics Economy
News headline image
Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen
Check out the companies making headlines yesterday: Cadence Design Systems (NASDAQ:CDNS): Electronic design automation company Cadence Design Systems (NASDAQ... 
Via StockStory
Topics Economy Electric Vehicles
News headline image
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead
Biogen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.7%. The stock now trades at $183.50, marking a 25.5% ga... 
Via StockStory
Topics Stocks
News headline image
Therapeutics Q4 Earnings: Novavax (NASDAQ:NVAX) Simply the Best
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Stock Trades Up, Here Is Why
What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.6% in the afternoon session after the company received an analyst upgrade from Wells F... 
Via StockStory
Topics World Trade
Top S&P500 movers in Monday's session ↗
Via Chartmill
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It? ↗
Or is the biotech's best days in the rearview mirror? 
Via The Motley Fool
News headline image
1 S&P 500 Stock for Long-Term Investors and 2 We Ignore
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
Wondering what's happening in today's S&P500 pre-market session? ↗
Via Chartmill
News headline image
1 Mid-Cap Stock with Promising Prospects and 2 We Brush Off
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco... 
Via StockStory
News headline image
Why Biogen Stock Got Mashed on Monday ↗
Its first-quarter expenses will be notably higher than anticipated. 
Via The Motley Fool
News headline image
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology
In a move that signals a decisive pivot for the biotechnology giant, Biogen Inc. (NASDAQ: BIIB) announced on March 31, 2026, that it has entered into a definitive agreement to acquire Apellis... 
Via MarketMinute
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
The Coiled Spring: Why Small-Caps are Poised for a Generational Productivity-Led Surge
As of April 3, 2026, the American equity market is witnessing a historic "Great Rotation" that many analysts believe could define the latter half of the decade. For the first time in over a... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
1 Cash-Producing Stock for Long-Term Investors and 2 We Turn Down
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa... 
Via StockStory
Topics Government Stocks World Trade
Discover which S&P500 stocks are making waves on Thursday. ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
In a move that has sent shockwaves through the biotechnology sector, Apellis Pharmaceuticals (Nasdaq: APLS) witnessed an extraordinary 135.7% surge in its share price on March 31, 2026. The massive... 
Via MarketMinute
News headline image
Why Biogen Stock Sank While the Market Soared on Thursday ↗
It's reaching into its coffers for a $5.6 billion acquisition. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.